There is news from the owners of the old Saab factory. After there had been first indications of liquidity shortages, the electric car Startup NEVS now receives another injection of cash from China.
New shareholder. Details and backgrounds unclear.
Behind the transfer of approximately 91 million € stands a company called Beijing Zhigan Shenghuo Technology, which is also a shareholder in NEVS from now on. How much and how shares have been acquired, for example through the issue of additional shares or through the departure of another shareholder, is unclear. There is no press release on the process, only the report in several Media.
The amount will not be enough to complete the Tainjin plant or to finance the start of production. But it will help over the coming months. The Chinese startup in the old Saab factory is hoping for Uber rival Didi to join as a major shareholder. A corresponding agreement is to be signed in autumn.
Important details in the local newspaper.
In the local newspaper Trollhättans was also reported by ex-CEO Bergman on profound changes. Again, there is no message to the media, although things would be important. There is only one paid article in the regional medium.
The changes in a compact form:
- NEVS has stopped the search for a new CEO, President Stefan Tilk takes over the position of Mattias Bergman in Personal Union permanently.
- The Tübitak Project, the development of a national car for Turkey, has been on ice for half a year and has failed.
- The start of series production for the NEVS 9-3 EV is planned for autumn 2018. It is estimated that by that time the plant in Tianjin has been completed in the appropriate condition.
- In the meantime, the old Saab factory is forging raw bodies and building prototypes.
- The licensing and homologation of the electric car by the Chinese authorities should be made 2018.
- The fact that the financial situation is not stable is confirmed to TTELA. Payments to partners and suppliers were late. The TTELA article was written prior to the announcement of the referral from China.